STAT1 activation represses IL-22 gene expression and psoriasis pathogenesis.

Area of Science:

• Immunology
• Molecular Biology
• Dermatology

Background:

• Interleukin-22 (IL-22) is a cytokine involved in tissue repair and inflammatory conditions like psoriasis.
• The precise molecular mechanisms governing IL-22 expression require further elucidation.
• STAT proteins are key signaling molecules in cytokine-mediated immune responses.

Purpose of the Study:

• To investigate the differential regulation of IL-22 expression in CD4+ T cells.
• To identify the roles of STAT1 and STAT3 in controlling IL-22 gene promoter activity.
• To explore the impact of STAT1 dysregulation on IL-22 production and psoriasis pathogenesis.

Main Methods:

• Stimulation of CD4+ T cells with IL-6 and IL-27.
• Chromatin immunoprecipitation (ChIP) assays to assess STAT protein binding to the IL-22 promoter.
• Luciferase reporter assays to quantify IL-22 promoter activity.
• Analysis of a heterozygous STAT1 mutation model in an imiquimod (IMQ)-induced psoriasis model.

Main Results:

• Rapid, differential regulation of IL-22 expression by IL-6 and IL-27 was observed.
• Both STAT1 and STAT3 directly bind to STAT responsive elements (SRE) in the IL-22 promoter.
• The balance between activated STAT1 and STAT3 dictates IL-22 promoter activity.
• Heterozygous STAT1 mutation led to increased IL-22 production and exacerbated skin inflammation in a murine psoriasis model.

Conclusions:

• STAT1 directly antagonizes STAT3 to regulate IL-22 expression, representing a novel regulatory mechanism.
• The balance between STAT1 and STAT3 is critical for controlling IL-22 production.
• STAT1-STAT3 balance plays a significant role in the pathogenesis of psoriasis.